BioSpace News Archive

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Sh

New executive brings over 20 years of experience serving as CFO for publicly-traded biopharmaceutical companies as Edgewise advances clinical muscular dystrophy program - BOULDER, Colo.--( BUSINESS WIRE )-- Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of R. Michael Carruthers to the newly created position of Chief Financial Officer

Aquarius Surgical Technologies, Inc is pleased to announce that John Bulicek has joined its business development team, as Vice President.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of George Llado, Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc., to its Board of Directors. Mr. Llado’s extensive experience leading information technology (IT) organizations in the biopharmaceutical industry will enhance the technological expertise of Charles River’s Board of Directors. As a

Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August 31, 2020. Net sales for the three months ended August 31, 2020 were $1.14 million compared to net sales of $1.19 million for the same period of 2019. Net loss was $1.6 million for the three months ended August 31, 2020 compared to a net loss of $0.5 million for the same period in the previous yea

- OMID Holdings, Inc. (OTC Pink: OMID), a publicly-traded health and wellness company, today provides Unaudited Key Financial Highlights for the third quarter. Operating Results for the Three Months Ended September 30, 2020 Revenue was $356,444 , compared to $178,435 for the same period last year, a 99.8% improvement. Gros

Affygility Solutions, a leading occupational health and safety consulting firm for the life sciences industry, announced today that its OEL Fastrac™️ platform has won the prestigious CPhI Excellence in Pharma Award for the Regulatory Procedures and Compliance category.

Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces the pricing of its initial public offering in the United States (the “Offering”) of 8,563,300 American Depositary Shares (“ADS”), representing 68,506,400 ordinary shares, at an initial public offering price of US$13.50 per ADS, before underwriting discounts

Photocure ASA announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC registry, an ongoing prospective multicenter study.

Avalyn Pharma Inc., a biopharmaceutical company focused on development of improved therapies for life threatening pulmonary diseases, announced completion of last patient in the initial 24 week evaluation of a Phase I/II clinical study of two dose regimens of AP01 in patients with idiopathic pulmonary fibrosis.